Risk Factors for Coronary Heart Disease Stephen B. Hulley Section 1: Epidemiology and Intervention: A Perspective on the Risk Factors 23 October 2012 Pages: 1 - 4
Experiences from Hypertension Trials — Effects on Stroke and Coronary Heart Disease Göran Berglund Section 1: Epidemiology and Intervention: A Perspective on the Risk Factors 23 October 2012 Pages: 5 - 8
Experiences from Hypertension Trials Ola Samuelsson Section 1: Epidemiology and Intervention: A Perspective on the Risk Factors 23 October 2012 Pages: 9 - 20
Lowering Lipids and the Genesis of Hypertension Lars-Göran Ekelund Section 1: Epidemiology and Intervention: A Perspective on the Risk Factors 23 October 2012 Pages: 21 - 21
Diabetes and Atherosclerosis George Steiner Section 1: Epidemiology and Intervention: A Perspective on the Risk Factors 23 October 2012 Pages: 22 - 26
Cholesterol Reduction and Coronary Artery Disease Matti J. TikkanenKalevi Pyörälä Section 1: Epidemiology and Intervention: A Perspective on the Risk Factors 23 October 2012 Pages: 27 - 31
Helsinki Heart Study Jussi K. HuttunenM. Heikki FrickHelsinki Heart Study Group Section 1: Epidemiology and Intervention: A Perspective on the Risk Factors 23 October 2012 Pages: 32 - 36
Regression of Coronary Atherosclerosis David D. WatersJacques Lespérance Section 1: Epidemiology and Intervention: A Perspective on the Risk Factors 23 October 2012 Pages: 37 - 42
Discussion Section 1 Section 1: Epidemiology and Intervention: A Perspective on the Risk Factors 23 October 2012 Pages: 43 - 45
Interaction of Lipoproteins with the Artery Wall Neville Woolf Section 2: Lipoprotein Metabolism: Treatment of Hypercholesterolaemia 23 October 2012 Pages: 46 - 50
Normal and Pathological Lipoprotein Metabolism Gilbert R. Thompson Section 2: Lipoprotein Metabolism: Treatment of Hypercholesterolaemia 23 October 2012 Pages: 51 - 54
The Lipoprotein Receptor Concept David W. Bilheimer Section 2: Lipoprotein Metabolism: Treatment of Hypercholesterolaemia 23 October 2012 Pages: 55 - 62
An Overview of Lipid-Lowering Drugs D. Roger Illingworth Section 2: Lipoprotein Metabolism: Treatment of Hypercholesterolaemia 23 October 2012 Pages: 63 - 71
Mechanism of Action and Biological Profile of HMG CoA Reductase Inhibitors Eve E. SlaterJames S. MacDonald Section 2: Lipoprotein Metabolism: Treatment of Hypercholesterolaemia 23 October 2012 Pages: 72 - 82
HMG CoA Reductase Inhibitors J. Findlay Walker Section 2: Lipoprotein Metabolism: Treatment of Hypercholesterolaemia 23 October 2012 Pages: 83 - 86
Clinical Experience with Simvastatin Compared with Cholestyramine D. W. ErkelensM. G. A. BaggenM. J. T. M. Mol Section 2: Lipoprotein Metabolism: Treatment of Hypercholesterolaemia 23 October 2012 Pages: 87 - 92
Discussion Section 2 Section 2: Lipoprotein Metabolism: Treatment of Hypercholesterolaemia 23 October 2012 Pages: 93 - 94
Population and Individual Strategies for the Prevention of Coronary Heart Disease Barry Lewis Section 3: Future Strategies 23 October 2012 Pages: 95 - 99
The US National Cholesterol Education Program Stephen B. Hulley Section 3: Future Strategies 23 October 2012 Pages: 100 - 104
Strategies for Dietary and Anti-Smoking Advice Ingvar Hjermann Section 3: Future Strategies 23 October 2012 Pages: 105 - 109
The Future of Pharmacological Therapy for Risk Factor Reduction Lennart Hansson Section 3: Future Strategies 23 October 2012 Pages: 110 - 114
The Future of Pharmacological Therapy for Risk Factor Reduction Anders G. OlssonJörgen Mölgaard Section 3: Future Strategies 23 October 2012 Pages: 115 - 120